Navigation Links
Cardiology Point of Care Diagnostics: Products, players & outlook to 2017
Date:12/13/2012

clinical-usefulness, convenience and cost in order to adopt them. Unsurprisingly, concerns have been raised by laboratory professionals about the decentralisation of hospital testing and by doctors about patient and consumer self-testing. In both cases, there is concern that the use of POC products by less skilled users may result in inaccurate diagnoses, leading to resistance to the changes needed for POC products to be widely implemented.
Overcoming these issues will be critical to the POC diagnostic sector if it is to realise its full potential – at present, adoption and usage rates vary widely, and there remains much untapped potential in the worldwide market.

Innovation is making an impact

There is currently much innovation in the market. Products that enable multi-parameter diagnostics using technologies such as microfluidics are a major focus, as are products for personalised medicine. For example, the first POC DNA analysis system, Spartan Bioscience's RX CYP2C19, has European approval to help identify patients with impaired metabolism to the popular anti-blood clotting medication, clopidogrel.

This new September 2012 report delivers a complete and insightful analysis

This new 130-page highly detailed report – Volume 1 of a 4-volume study of the whole IVD sector to be published this autumn/winter – provides executives with a complete understanding of the issues which are shaping the market and how they will affect its commercial development.

Get the best from your investment! Pdf or print formats and the brilliant Espicom Interactive included at no extra cost! Customers can choose print or pdf format but all get access via Espicom Interactive. Customers will really benefit from accessing this report's rich content through Espicom Interactive by...
Accessing daily-reviewed company reports, updates and news
Intuitively cross file searching and getting fast results
Saving time and ef
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
2. Leading Cardiology Experts Advice on Dietary Supplement Niacins: Make Informed Choices at the Shelf and Scan the Label for Nicotinic Acid
3. Philips and Corindus announce distribution agreement to sell Corindus robotic-assisted interventional cardiology system in the United States
4. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
5. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
6. 50% of U.S. News & World Reports "Best Hospitals" for Cardiology & Heart Surgery Making the SynCardia Total Artificial Heart Part of Their Toolbox
7. Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. AAIPharma Appoints Senior Director of Biopharmaceutical Development
10. uniQure Appoints Hans Christian Rohde Chief Commercial Officer
11. CIVCO Medical Solutions Appoints Senior Vice President and General Managers to Business Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... , ENGLEWOOD, Colo., Dec. 7 ... DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting (MCM). ... safety and pharmacy efficiency through the management of IV ... into current pharmacy practice and techniques, while providing a ...
... , CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: ... the Company,s participation at the Deutsche Bank 2009 MedTools Investor ... Mass. on December 9-10, 2009. , Genoptix,s EVP ... the Company on Wednesday, December 9, 2009. He will ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... Santa Clara, CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 ... The National Football League’s biggest day each year is the Super Bowl. In the ... buildup that takes place from the host venue. The 2016 Super Bowl game will mark ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last ... by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , ... are customizable. The best part: whenever a product is purchased, the Meso Foundation ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... 28 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ... and commercialization of proprietary products that address important therapeutic ... Glenn A. Oclassen, President & Chief Executive Officer, is ... Science Conference in New York City on Wednesday, June ...
... LaboratoryALBUQUERQUE, N.M., May 28 Exagen Diagnostics, Inc. today ... to assist physicians with diagnosing Irritable Bowel Syndrome (IBS) ... tests at Digestive Disease Week 2009 in Chicago, May ... identifies patients with IBS, while the eXaIBD ...
... to Vote WHITE Proxy Card to Re-Elect Highly-Qualified ... Opposition SlateTUCSON, Ariz., May 28 The Providence ... announced that it has issued the following letter ... to vote at the upcoming 2009 Annual Meeting ...
... Quality, Cutting CostsSILVER SPRING, Md., May 28 ... outcomes management systems, today issued a white paper ... Congress to require consumer-driven outcomes management as a ... industry. "Consumer-Driven Outcomes Management: A New Paradigm for ...
... May 28 NXGen Holdings, Inc. (Pink Sheets: ... is entering the $17.5 Billion Household and Industrial ... Green Bridge Industries, Inc., a company which manufactures ... NXGen Holdings, Inc. acquired Green Bridge Industries in ...
... Data To Be Presented at 2009 ASCO Annual ... Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic ... Host Analyst and Investor Briefing to Discuss Data ... Calif., May 28 Poniard Pharmaceuticals, Inc. (Nasdaq: ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 2Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 3Health News:Exagen Launches New Diagnostic Assays for Bowel Disease at Digestive Disease Week Conference 2Health News:Providence Service Corporation Issues Letter to Stockholders 2Health News:Providence Service Corporation Issues Letter to Stockholders 3Health News:Providence Service Corporation Issues Letter to Stockholders 4Health News:Providence Service Corporation Issues Letter to Stockholders 5Health News:Providence Service Corporation Issues Letter to Stockholders 6Health News:Providence Service Corporation Issues Letter to Stockholders 7Health News:Providence Service Corporation Issues Letter to Stockholders 8Health News:Providence Service Corporation Issues Letter to Stockholders 9Health News:MyOutcomes Urges Government Leaders to Employ Consumer-Driven Outcomes Management in Reforming Behavioral Health System 2Health News:MyOutcomes Urges Government Leaders to Employ Consumer-Driven Outcomes Management in Reforming Behavioral Health System 3Health News:NXGen Holdings, Inc. Enters the $17.5 Billion Household and Industrial Cleaning Products Industry through the Acquisition of Green Bridge Industries, Inc. 2Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 2Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 3Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 4Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 5Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 6
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... VISIPAQUE is the only isosmolar contrast medium (IOCM) ... to that of blood, VISIPAQUE was designed for ... only contrast medium formulated with sodium and calcium ... VISIPAQUE received FDA approval for use in children ...
... (iopromide) injection is a nonionic, iodinated, ... administration. Introduced in the U.S. in ... in Europe, ULTRAVIST today is ... has established a positive clinical experience ...
Medicine Products: